Relationship Between Frontal QRS-T Angle and Non-Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score in Patients with Stable Angina Pectoris
Abstract
1. Introduction
2. Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Oehler, A.; Feldman, T.; Henrikson, C.A.; Tereshchenko, L.G. QRS-T angle: A review. Ann. Noninvasive Electrocardiol. 2014, 19, 534–542. [Google Scholar] [CrossRef] [PubMed]
- Akın, H.; Bilge, Ö. Relationship between frontal QRS-T duration and the severity of coronary artery disease in those who were non-diabetic and had stable angina pectoris. Anatol. J. Cardiol. 2021, 25, 572–578. [Google Scholar] [CrossRef] [PubMed]
- Giannopoulos, G.; Dilaveris, P.; Batchvarov, V.; Synetos, A.; Hnatkova, K.; Gatzoulis, K.; Malik, M.; Stefanadis, C. Prognostic significance of inverse spatial QRS-T angle circadian pattern in myocardial infarction survivors. J. Electrocardiol. 2009, 42, 79–84. [Google Scholar] [CrossRef] [PubMed]
- Aro, A.L.; Huikuri, H.V.; Tikkanen, J.T.; Junttila, M.J.; Rissanen, H.A.; Reunanen, A.; Anttonen, O. QRS-T angle as a predictor of sudden cardiac death in a middle-aged general population. Europace 2012, 14, 872–876. [Google Scholar] [CrossRef]
- De Bruyne, B.; Fearon, W.F.; Pijls, N.H.; Barbato, E.; Tonino, P.; Piroth, Z.; Jagic, N.; Mobius-Winckler, S.; Rioufol, G.; Witt, N.; et al. FAME 2 Trial Investigators. Fractional flow reserve-guided PCI for stable coronary artery disease. N. Engl. J. Med. 2014, 371, 1208–1217. [Google Scholar] [CrossRef]
- Vieira Barbosa, J.; Lai, M. Nonalcoholic fatty liver disease screening in type 2 diabetes mellitus patients in the primary care setting. Hepatol. Commun. 2020, 5, 158–167. [Google Scholar] [CrossRef]
- Gummesson, A.; Strömberg, U.; Schmidt, C.; Kullberg, J.; Angeras, O.; Lindgren, S.; Hjelmgren, O.; Torén, K.; Rosengren, A.; Fagerberg, B.; et al. Non-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects. A cross-sectional, population-based study in middle-aged subjects. PLoS ONE 2018, 13, e0202666. [Google Scholar] [CrossRef]
- Hassen, G.; Singh, A.; Belete, G.; Jain, N.; De la Hoz, I.; Camacho-Leon, G.P.; Dargie, N.K.; Carrera, K.G.; Alemu, T.; Jhaveri, S.; et al. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. Cureus 2022, 14, e25495. [Google Scholar] [CrossRef]
- Kim, C.H.; Younossi, Z.M. Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome. Cleve Clin. J. Med. 2008, 75, 721–728. [Google Scholar] [CrossRef]
- Campos-Murguía, A.; Ruiz-Margáin, A.; González-Regueiro, J.A.; Macías-Rodríguez, R.U. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J. Gastroenterol. 2020, 26, 5919–5943. [Google Scholar] [CrossRef]
- Angulo, P.; Hui, J.M.; Marchesini, G.; Bugianesi, E.; George, J.; Farrell, G.C.; Enders, F.; Saksena, S.; Burt, A.D.; Bida, J.P.; et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45, 846–854. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.M.; Prineas, R.J.; Case, D.; Soliman, E.Z.; Rautaharju, P.M.; ARIC Research Group. Comparison of the prognostic significance of the electrocardiographic QRS/T angles in predicting incident coronary heart disease and total mortality (from the atherosclerosis risk in communities’ study). Am. J. Cardiol. 2007, 100, 844–849. [Google Scholar] [CrossRef]
- Chalasani, N.; Younossi, Z.; Lavine, J.E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S.A.; Brunt, E.M.; Sanyal, A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018, 67, 328–357. [Google Scholar] [CrossRef]
- Ichikawa, K.; Miyoshi, T.; Osawa, K.; Miki, T.; Toda, H.; Ejri, K.; Yoshida, M.; Nanba, Y.; Nakamura, K.; Morita, H.; et al. Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: A prospective cohort study. Cardiovasc. Diabetol. 2021, 20, 8. [Google Scholar] [CrossRef]
- Paschos, P.; Paletas, K. Non-alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009, 13, 9–19. [Google Scholar] [PubMed]
- Anstee, Q.M.; Mantovani, A.; Tilg, H.; Targher, G. Risk of cardiomyopathy and cardiac arrhythmias in patients with non-alcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 425–439. [Google Scholar] [CrossRef]
- Zhao, Y.C.; Zhao, G.I.; Chen, Z.; She, Z.G.; Cai, J.; Li, H. Nonalcoholic fatty liver disease: An emerging driver of hypertension. Hypertension 2020, 75, 275–284. [Google Scholar] [CrossRef]
- Kızılırmak, P.; Öngen, Z.; Kayıkçıoğlu, M.; Tokgözoğlu, L. Evaluation of statin use on LDL cholesterol levels in Turkey: A systematic review. Turk. Kardiyol. Dern. Ars. 2020, 48, 137–148. [Google Scholar] [CrossRef]
- Polyzos, S.A.; Kountouras, J.; Mantzoros, C.S. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019, 92, 82–97. [Google Scholar] [CrossRef]
- Maurice, J.; Manousou, P. Non-alcoholic fatty liver disease. Clin. Med. 2018, 18, 245–250. [Google Scholar] [CrossRef]
- Targher, G.; Valbusa, F.; Bonapace, S.; Bertolini, L.; Zenari, L.; Rodella, S.; Zoppini, G.; Mantovani, W.; Barbieri, E.; Byrne, C.D.; et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS ONE 2013, 8, e57183. [Google Scholar] [CrossRef] [PubMed]
- Gaggini, M.; Minichilli, F.; Gorini, F.; Del Turco, S.; Landi, P.; Pingitore, A.; Vassalle, C. FIB-4 Index and Neutrophil-to-Lymphocyte Ratio as Death Predictors in Coronary Artery Disease Patients. Biomedicines 2022, 11, 76. [Google Scholar] [CrossRef] [PubMed]
- European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL-EASD-EASOClinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. J. Hepatol. 2016, 64, 1388–1402. [CrossRef]
- Golabi, P.; Paik, J.M.; Eberly, K.; de Avila, L.; Alqahtani, S.A.; Younossi, Z.M. Causes of death in patients with non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, and chronic viral hepatitis B and C. Ann. Hepatol. 2022, 27, 100556. [Google Scholar] [CrossRef]
- Wu, T.; Ye, J.; Gong, X.; Li, X.; Shao, C.; Li, F.; Lin, Y.; Ma, Q.; Mai, W.; Wang, W.; et al. Apolipoproteins and liver parameters optimize cardiovascular disease risk stratification in nonalcoholic fatty liver disease. Dig. Liver Dis. 2021, 53, 1610–1619. [Google Scholar] [CrossRef]
- Choudhary, N.S.; Duseja, A. Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How? J. Clin. Exp. Hepatol. 2019, 9, 506–514. [Google Scholar] [CrossRef]
Variable | NAFLDH < 0.67 (N = 155) | NAFLDH ≥ 0.67 (N = 22) | p |
---|---|---|---|
Demographic Data | |||
Gender (Male) n (%) | 114 (73.5) | 15 (68.2) | 0.382 |
Age (Year) | 55.8 ± 12.4 | 71.6 ± 7.4 | <0.001 |
Hypertension n (%) | 76 (49) | 17 (77.3) | 0.011 |
Dyslipidemia n (%) | 42 (27.1) | 9 (40) | 0.139 |
Diabetes Mellitus n (%) | 33 (21.3) | 12 (54.5) | 0.002 |
Previous Stent n (%) | 53 (34.2) | 10 (45.5) | 0.305 |
Coronary artery disease n (%) | 96 (61.9) | 21 (95.5) | 0.002 |
Body mass index (kg/m2) | 28.9 ± 4.5 | 30.3 ± 4.7 | 0.173 |
Current Smoking n (%) | 68 (43.9) | 7 (31.8) | 0.201 |
Medication | |||
Aspirin n (%) | 62 (40) | 12 (54) | 0.144 |
P2Y12 Inhibitors n (%) | 4 (2.6) | 3 (13.6) | 0.042 |
ACEI n (%) | 35 (22.6) | 10 (45.5) | 0.024 |
ARB (%) | 31 (20) | 4 (18.2) | 0.552 |
Beta Blocker n (%) | 42 (27.1) | 11 (50) | 0.029 |
Calcium channel blocker n (%) | 13 (8.4) | 4 (18.2) | 0.142 |
Statin n (%) | 24 (15.5) | 6 (27.3) | 0.168 |
Oral antidiabetic n (%) | 28 (18.1) | 10 (45.5) | 0.006 |
Insulin n (%) | 7 (4.5) | 2 (9.1) | 0.310 |
Laboratory Data | |||
Glucose (mg/dL) | 111.9 ± 35 | 147 ± 74 | <0.001 |
Se Creatinine (mg/dL) | 0.91 ± 0.26 | 1.02 ± 0.23 | 0.075 |
White blood cell (103/μL) | 8.4 ± 2.33 | 9.1 ± 3.1 | 0.174 |
Neutrophil (103/μL) | 5.4 ± 2.1 | 6.6 ± 2.9 | 0.021 |
Hemoglobin (gr/dL) | 14.1 ± 1.8 | 13.2 ± 2.1 | 0.034 |
Platelet (103/μL) | 253 ± 71 | 187 ± 37 | <0.001 |
Aspartate aminotransferase (IU/L) | 24.5 ± 9.9 | 42.5 ± 30.8 | <0.001 |
Alanine aminotransferase (IU/L) | 23.9 ± 12.6 | 21.4 ± 11.1 | 0.391 |
Albumin (g/dL) | 4.2 ± 0.3 | 3.83 ± 0.82 | <0.001 |
Total cholesterol (mg/dL) | 207 ± 48 | 177 ± 37 | 0.006 |
Low-density lipoprotein (mg/dL) | 134 ± 39 | 109 ± 34 | 0.005 |
High-density lipoprotein (mg/dL) | 46 ± 12 | 44 ± 10.6 | 0.344 |
Triglyceride (mg/dL) | 154.7 ± 74 | 133.4 ± 60 | 0.200 |
Electrocardiographic Data | |||
Pathologic Q n (%) | 31(20) | 8 (36.4) | 0.077 |
Fragmented QRS n (%) | 44 (28.6) | 9 (40.9) | 0.175 |
QRS Time (ms) | 96.3 ± 14.3 | 105.1 ± 17.7 | 0.010 |
P-Max (ms) | 103.02 ± 6.5 | 107.1 ± 11.2 | 0.019 |
P-Min (ms) | 57.2 ± 5.4 | 59.7 ± 9.6 | 0.086 |
P-Dispersion (ms) | 45.7 ± 4.1 | 47.7 ± 4.7 | 0.048 |
QT Interval (ms) | 391 ± 34 | 405 ± 43 | 0.106 |
QTc Interval (ms) | 416 ± 26 | 431 ± 31 | 0.018 |
R Peak Time (ms) | 35.1 ± 11 | 40.8 ± 13.1 | 0.047 |
Frontal QRS-T Angle (°) | 24 (14–92) | 118 (78–149) | <0.001 |
Frontal QRS-T Angle (Log) (°) | 3.2 ± 1.1 | 4.4 ± 0.73 | <0.001 |
Univariate | Multivariate | |||||
---|---|---|---|---|---|---|
Variable | OR | 95% CI | p | OR | 95% CI | p |
Hypertension | 3.354 | 1.242–10.02 | 0.018 | |||
Coronary artery disease | 12.91 | 1.691–98.84 | 0.014 | |||
Neutrophil | 1.231 | 1.027–1.475 | 0.024 | |||
Hemoglobin | 0.791 | 0.635–0.987 | 0.038 | |||
Total cholesterol | 0.986 | 0.975–0.996 | 0.007 | |||
Low-density lipoprotein | 0.982 | 0.969–0.995 | 0.007 | 0.984 | 0.970–0.998 | 0.024 |
QRS Time | 1.032 | 1.006–1.059 | 0.015 | |||
P-Max | 1.064 | 1.007–1.124 | 0.026 | |||
P-Dispersion | 1.108 | 0.999–1.228 | 0.052 | |||
QTc Interval | 1.019 | 1.003–1.035 | 0.020 | |||
R Peak Time | 1.032 | 0.999–1.067 | 0.055 | |||
Frontal QRS-T Angle (Log) | 3.314 | 1.840–5.699 | <0.001 | 3.472 | 1.886–6.395 | <0.001 0.002 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Özyıldız, A.G.; Özyıldız, A.; Durak, H.; Emlek, N.; Çetin, M. Relationship Between Frontal QRS-T Angle and Non-Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score in Patients with Stable Angina Pectoris. J. Clin. Med. 2025, 14, 5117. https://doi.org/10.3390/jcm14145117
Özyıldız AG, Özyıldız A, Durak H, Emlek N, Çetin M. Relationship Between Frontal QRS-T Angle and Non-Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score in Patients with Stable Angina Pectoris. Journal of Clinical Medicine. 2025; 14(14):5117. https://doi.org/10.3390/jcm14145117
Chicago/Turabian StyleÖzyıldız, Ali Gökhan, Afag Özyıldız, Hüseyin Durak, Nadir Emlek, and Mustafa Çetin. 2025. "Relationship Between Frontal QRS-T Angle and Non-Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score in Patients with Stable Angina Pectoris" Journal of Clinical Medicine 14, no. 14: 5117. https://doi.org/10.3390/jcm14145117
APA StyleÖzyıldız, A. G., Özyıldız, A., Durak, H., Emlek, N., & Çetin, M. (2025). Relationship Between Frontal QRS-T Angle and Non-Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score in Patients with Stable Angina Pectoris. Journal of Clinical Medicine, 14(14), 5117. https://doi.org/10.3390/jcm14145117